Brucella abortus strain RB51 was recently approved as an official brucellosis calfhood vaccine for cattle by the Animal and Plant Health Inspection Service branch of the United States Department of Agriculture. Currently available serologic surveillance tests for B. abortus do not detect seroconversion following SRB51 vaccination. The purpose of this study was to evaluate a dot-blot assay using ␥-irradiated strain RB51 bacteria for its specificity and sensitivity to detect antibody responses of cattle vaccinated with strain RB51. Dot-blot titers of sera at a recommended dosage (10 10 colony-forming units) were similar to those of sera from cattle vaccinated with similar numbers of B. abortus strain 19 and greater (P Ͻ 0.05) than titers of nonvaccinated cattle. In the first 12 weeks after vaccination with 10 10 colony-forming units of strain RB51, the RB51 dot-blot assay had 100% specificity for titers of 80 or less and a 53% sensitivity for titers of 160 or greater. Sensitivity of the RB51 dot-blot assay peaked at 4 weeks after vaccination with 10 10 colony-forming units of strain RB51. Dot-blot responses of sera from cattle vaccinated with a reduced dosage of strain RB51 (10 9 colony-forming units) did not differ (P Ͼ 0.05) from titers of sera from nonvaccinated cattle. Following intraconjunctival challenge with B. abortus strain 2308, titers on the RB51 dot-blot assay did not differ (P Ͼ 0.05) between nonvaccinated cattle and cattle vaccinated at calfhood with strain 19 or strain RB51.
Currently available serologic surveillance tests for Brucella abortus are all based on detecting antibodies against the lipopolysaccharide (LPS) O-side chain. 12 The inability to serologically differentiate the current brucellosis calfhood vaccine, B. abortus strain 19 (S19), from field infections has stimulated interest in the development of a new brucellosis vaccine for cattle. Recently, B. abortus strain RB51 (SRB51), a laboratory-derived mutant of B. abortus strain 2308 (S2308) 8 deficient in the LPS O-side chain, was approved as a official brucellosis calfhood vaccine by the Animal and Plant Health Inspection Service branch of the United States Department of Agriculture. The SRB51 vaccine is protective when administered to calves between 3 and 10 months of age [2] [3] [4] and does not induce seropositive responses on brucellosis surveillance tests. 11 Administration of SRB51 to adult cattle does not cause positive responses on brucellosis surveillance tests even when administered to cattle that received S19 as a calfhood vaccine. 6 It is anticipated that replacement of S19 with SRB51 for calfhood vaccination will facilitate the identification and removal of cattle infected with brucellosis from vaccinated herds. A commercial SRB51 vaccine has recently become available.
Although serologic responses cannot be detected in SRB51-vaccinated cattle using current brucellosis tests, a dot-blot assay has been developed to monitor antibody responses following SRB51 vaccination. The purpose of this study was to determine the sensitivity and specificity of the RB51 dot-blot assay using sera samples obtained from experimentally vaccinated cattle. The influence of S19 vaccination or mid-gestational challenge with virulent S2308 on responses in the SRB51 dot-blot assay also were determined.
Materials and methods
Brucella cultures. A preparation of the master seed stock of B. abortus SRB51 a was used in the experiment. After one passage on tryptose agar, this seed stock was designated ARS-1. For experimental use, SRB51 (ARS-1) bacteria were grown on tryptose agar containing 5% bovine serum for 48 hr at 37 C. The bacteria were removed from the agar by aspiration using phosphate-buffered saline (PBS, 0.15 M NaCl, pH 7.2) and concentrated by centrifugation. Brucella abortus strain 2308 b was grown in trypticase soy broth for 48 hr in a fermenter. The bacteria were harvested, washed twice in PBS, and concentrated. Killed SRB51 (1.3 ϫ 10 12 colony-forming units [CFU]/ml) were prepared by ␥-irradiation (1.4 ϫ 10 6 rads) of bacterial suspensions. Following irradiation, suspensions were washed in PBS and stored in 1-ml aliquots at Ϫ70 C.
In addition to the studies using the ARS-1 stock of SRB51, a commercial, ARS-1-derived, lyophilized preparation of SRB51 c was obtained for evaluation and prepared according to manufacturer's directions.
Vaccination experiments. Hereford heifers from brucellosis-free herds that had not been vaccinated with S19 were Figure 1 . Postvaccination serologic responses by cattle in a dot-blot assay using ␥-irradiated SRB51. Cattle (3-10 months of age) were subcutaneously vaccinated with SRB51 (0.85-1.6 ϫ 10 10 CFU, n ϭ 58) or saline (4 ml, n ϭ 36). Data are presented as means Ϯ SEM from 6 separate experiments. Means with different superscripts differ significantly (P Ͻ 0.05). obtained and maintained in pastures at the National Animal Disease Center. Between the ages of 3 and 18 mo (3, 5, 7, 10, and 18 mo), 58 heifers were vaccinated with SRB51 (8.5 ϫ 10 9 to 1.6 ϫ 10 10 CFU total dose) in 6 separate studies to evaluate the efficacy of SRB51 as a vaccine to prevent brucellosis. All vaccine dosages were suspended in 4 ml PBS, with both right and left cervical regions receiving subcutaneous injections (2 ml per side). In 3 of these experiments, 16 additional heifers were vaccinated with S19 (0.98-1.75 ϫ 10 10 CFU) at age 3, 5, or 7 mo. In each study, randomly selected heifers (n ϭ 26) were bilaterally inoculated with 4 ml PBS (2 ml per side) for use as controls.
In addition to the studies described above, a separate efficacy study investigating the dose response to SRB51 also was conducted. Hereford heifers from a brucellosis-free herd were vaccinated at age 3 mo with a commercial SRB51 vaccine resuspended in 2 ml PBS. Heifers were vaccinated in the right axillary region with either 1.3 ϫ 10 10 CFU SRB51 (n ϭ 15) or 1.0 ϫ 10 9 CFU SRB51 (n ϭ 6). Control animals (n ϭ 6) received 2 ml PBS.
Blood samples were collected by jugular venipuncture prior to vaccination and, depending upon the experiment, at regular intervals up to 12 wk after vaccination. Blood was allowed to clot for 12 hr at 4 C and centrifuged. Serum was divided into 1-ml aliquots, frozen, and stored at -70 C.
Postchallenge experiments. The influence that infection with a virulent B. abortus strain has on dot-blot titers was also determined. Cattle were vaccinated at calfhood with SRB51, S19, or saline as described above, raised to maturity, pasture-bred at 15-17 mo, and challenged intraconjunctivally at 180 days gestation with 1 ϫ 10 7 CFU of B. abortus strain 2308. Cattle were randomly selected for evaluation from 3 experiments that included S19 vaccination (at 3, 5, or 7 mo; n ϭ 16/treatment). Blood was collected, before challenge and at 4 and 8 wk after challenge, and processed and stored as described above.
Dot-blot assay. The dot-blot assay was conducted as previously described. 4 Briefly, a stock solution for SRB51 was made by spectrophotometric adjustment of killed bacteria to 20% transmission at 600 nm. A 96-well microfiltration unit d was prepared using a nitrocellulose membrane e with a pore size of 0.45 m. Thirty microliters of the SRB51 suspension was added to each well and incubated for 30 min at room temperature. After the membrane was dried by applying a vacuum, the membrane was blocked by addition of 100 l 0.02 M Tris and 0.5 M NaCl buffer (Tris-NaCl, pH 7.5) containing 0.25% fish gelatin f (Tris-FG) to each well. Following a 30-min incubation, the membrane was washed twice using 100 l Tris-NaCl containing 0.3% Tween 20 g (Tris-NaCl-Tween) and dried by vacuum. Serum samples were prepared in Tris-FG at 2-fold dilutions beginning at a 1:20 dilution. Positive and negative control sera were also prepared. Thirty microliters of each serum dilution and positive and negative controls was added to separate wells of the microfiltration unit. Following a 30-min incubation, the nitrocellulose was dried by vacuum and washed 5 times with 100 l per well of Tris-NaCl-Tween. The secondary antibody, peroxidase-conjugated rabbit anti-bovine IgG (heavy and light chain specific), h was diluted 1:10,000 in Tris-FG. A 100-l aliquot of the secondary antibody was added to each well and incubated for 30 min at room temperature. Each well was then washed 5 times with 100 l Tris-NaCl-Tween and dried for 30 sec under vacuum. The nitrocellulose membrane was then removed from the microfiltration unit and incubated for 10 min in Tris-NaCl containing 0.5 mg 4-chloro-1-napthol g /ml and 0.15% H 2 O 2 . g Membranes were dried in the dark for 12 hr at room temperature before interpretation. Results were expressed as the highest serum titer that produced a visible color reaction that was greater than the reaction for a negative serum sample.
Standard tube agglutination test. Serologic responses after innoculation with saline and vaccination with SRB51 or S19, or after challenge with B. abortus strain 2308, were determined by the standard tube agglutination test (STAT). 1 Statistical analysis. Data were analyzed by a repeated measures, general linear model procedure. For statistical Figure 2 . Serologic responses of SRB51-, S19-, or nonvaccinated cattle in a SRB51 dot-blot assay. Cattle (3-10 months of age) were subcutaneously vaccinated with SRB51 (0.85-1.22 ϫ 10 10 CFU, n ϭ 18), S19 (0.98-1.7 ϫ 10 10 CFU, n ϭ 16), or saline (4 ml, n ϭ 15). Data are presented as means Ϯ SEM from 3 separate experiments. Means with different superscripts differ significantly (P Ͻ 0.05). comparisons, data were evaluated as the logarithm of the titer. Means between treatment groups were compared by a least significant difference procedure. Data are presented as mean Ϯ SEM with significant differences reported when P Յ 0.05.
Results
Titers from SRB51-vaccinated or nonvaccinated cattle on the RB51 dot-blot assay did not differ prior to vaccination (Fig. 1 ). Cattle vaccinated with SRB51 had significantly greater (P Ͻ 0.01) titers at 2, 4, 8, and 12 weeks postvaccination when compared to cattle inoculated with saline. Cattle vaccinated with S19 had RB51 dot-blot responses that were statistically greater (P Ͻ 0.05) at 4 weeks, but not at 8 weeks after vac-cination, when compared to SRB51-vaccinated cattle (Fig. 2) . In the 6 studies evaluated, age at vaccination (3-18 months) did not statistically influence RB51 dotblot titers (P Ͼ 0.05).
In the dose-response experiment, RB51 dot-blot responses from cattle vaccinated with 1.3 ϫ 10 10 CFU SRB51 were statistically greater (P Ͻ 0.05) than nonvaccinated cattle at 2, 4, and 8 weeks, but not at 12 weeks postvaccination (Fig. 3) . In contrast, responses of cattle vaccinated with 1.0 ϫ 10 9 CFU SRB51 did not differ at any sampling time from nonvaccinated cattle. The higher dose of SRB51 induced statistically greater (P Ͻ 0.05) RB51 dot-blot titers only at 4 weeks postvaccination when compared to cattle vaccinated with 1.0 ϫ 10 9 CFU SRB51 (Fig. 3) . † Specificity is percent of nonvaccinates equal to or less than titer threshold.
‡ Titers presented as the reciprocal of the greatest dilution demonstrating positive response.
§ Confidence interval (95%) for overall mean.
Figure 4.
Postchallenge serologic responses by cattle in a SRB51 dot-blot assay. Cattle were vaccinated between 3 and 10 months of age with SRB51 (0.85-1.22 ϫ 10 10 CFU, n ϭ 16), S19 (0.98-1.7 ϫ 10 10 CFU, n ϭ 16), or saline (4 ml, n ϭ 16); raised to maturity; and intraconjunctivally challenged at 180 days of gestation with 1 ϫ 10 7 CFU S2308. Data are presented as means Ϯ SEM from 3 separate experiments. Means with different superscripts differ significantly (P Ͻ 0.05).
The specificity of the RB51 dot-blot assay was 100% when a titer of 80 or less was used as the threshold (Table 1 ). Lowering the threshold to a titer of 40 or less reduced the overall specificity to 96%. The RB51 dot-blot assay had an overall sensitivity of 54% when a titer of 160 or more was used as the threshold. Raising the threshold value to 320 or more reduced sensitivity to 33%.
All cattle were negative at a 1:25 dilution on the STAT test prior to vaccination. Cattle vaccinated with SRB51 remained negative at a 1:25 dilution on the STAT at all times following vaccination, whereas S19 vaccinates had increased (P Ͻ 0.05) STAT titers (data not shown). Following challenge at mid-gestation with S2308, all animals demonstrated positive responses on the STAT (data not shown). However, postchallenge RB51 dot-blot titers of SRB51-and S19-vaccinated animals did not differ from titers of S2308-challenged, nonvaccinated cattle (Fig. 4 ).
Discussion
Many serologic tests based on antibodies against the LPS O-side chain are currently available for detection of cattle infected with B. abortus. 12 However, none of these tests can be used to monitor humoral responses following vaccination with SRB51. 6, 11 The specificity and sensitivity of the RB51 dot-blot assay has not been characterized, although this assay is currently the only test being used to monitor responses of cattle after SRB51 vaccination. The data indicate that the RB51 dot-blot assay is highly specific in detecting antibody titers during the first 8 weeks after vaccination with 10 10 CFU SRB51, but at 12 weeks the sensitivity dramatically declines.
The data also suggest that calfhood vaccination of cattle with 10 9 CFU SRB51 may not induce antibody responses that can be differentiated from nonvaccinated cattle on the RB51 dot-blot assay. However, only 6 animals were vaccinated with 10 9 CFU of SRB51, and we cannot exclude the possibility that some animals vaccinated with this dose might be identified using the RB51 dot-blot assay. The lack of response on the RB51 dot-blot assay may be of minor diagnostic importance because 10 9 CFU SRB51 is less than the current recommendation of between 1 and 3.4 ϫ 10 10 CFU SRB51 vaccine at calfhood. It is assumed that antibodies to SRB51 do not play a protective role in cattle based on passive transfer studies in mice. 5 Therefore, the inability to detect antibody responses at this SRB51 dosage does not have implications in regards to its efficacy in preventing infection or abortion.
The data suggest that the RB51 dot-blot assay will not differentiate between S19-and SRB51-vaccinated calves since both vaccine strains induced similar titers. However, these titers do not appear to persist because both S19 and SRB51 vaccinates had minimal responses on the RB51 dot-blot assay when evaluated prior to challenge at 2 years of age.
Responses on the RB51 dot-blot assay do not appear to be influenced by infection with S2308 during the first 10 weeks postchallenge. This may suggest that field infections of pregnant cattle with smooth B. abortus strains will not induce detectable titers in SRB51vaccinates on the RB51 dot-blot assay. This lack of response after challenge is apparently not due to differences between the outer membrane proteins (OMPs) of S2308 and SRB51 because gel electrophoresis, immunodiffusion, and counter immunoelectrophoresis techniques indicate that the OMPs of these 2 strains are similar. 7 Also, data from lymphocyte proliferation assays suggest that protein antigens of the 2 strains are similar. 9, 10 The lack of detectable RB51 dot-blot titers in sera from SRB51 and S19 vaccinates after challenge may reflect the differences between vaccination and challenge dosages (10 10 vs. 10 7 CFU), route of administration (subcutaneous injection vs. intraconjunctival inoculation), pregnancy status of the animal, or a combination thereof. However, it should be noted that STAT titers of most cattle in S19, SRB51, and control treatment groups peak within 2-4 weeks postchallenge with S2308, indicating immune recognition of the challenge strain. Because SRB51 has minimal expression of the O-side chain, 8 an alternative hypothesis may be that during the first 10 weeks following infection of pregnant cattle with smooth strains of B. abortus, the predominant antibody response is against the LPS O-side chain rather than OMPs, even in cattle previously responding to OMP antigens following vaccination with SRB51 or S19.
